newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Moneycontrol
AstraZeneca Pharma India shares fell nearly 7 percent in Wednesday's trade.
AstraZeneca Pharma India reported a 23 percent decline in net profit for Q4 FY26.
KEY POINTS
Revenue from operations rose 20.42 percent to Rs 578.61 crore during Q4 FY26.
Despite quarterly profit drop, full FY26 net profit rose 62 percent to Rs 187.52 crore.
Total expenses for the March quarter increased 27.36 percent to Rs 525.34 crore.
AstraZeneca Pharma India shares fell nearly 7 percent in Wednesday's trade after the company reported a 23 percent decline in net profit for the March quarter of FY26.
The stock declined 6.76 percent to an intraday low of Rs 8,357 per share on the NSE, snapping a two-day gaining streak following the announcement of its quarterly results.
The company posted a net profit of Rs 44.88 crore for the January-March quarter of FY26, compared with Rs 58.25 crore in the corresponding quarter last year.
However, revenue from operations rose 20.42 percent to Rs 578.61 crore during the quarter under review from Rs 480.48 crore a year ago.
Total expenses in the March quarter increased 27.36 per cent to Rs 525.34 crore.
Market analysts said the decline in the stock was largely due to profit booking and did not indicate a reversal in the broader trend.
Kunal Kamble, Senior Technical Research Analyst at Bonanza Portfolio, said AstraZeneca Pharma India is trading in a broad consolidation phase on the weekly chart after a strong uptrend.
"The stock is holding above its key long-term moving averages, while the 50-week EMA near 8,100 is acting as immediate support. A descending trendline resistance is placed around 8,500-8,600, and a breakout above this zone may trigger fresh bullish momentum towards 9,200 and 10,000 levels," he said.
He added that the RSI is hovering near the neutral 50 mark, indicating gradual recovery in strength, while volume activity remains stable, reflecting accumulation at lower levels.
"Positional bias remains positive while the stock sustains above 7,850 support," Kamble said.
For the full FY26, AstraZeneca Pharma India reported a 62 percent rise in net profit to Rs 187.52 crore.
Total revenue for the financial year ended March 31 increased 32.58 percent to Rs 2,275.58 crore.